Nirmatrelvir plus ritonavir for early COVID-19 and hospitalization in a large US health system

BACKGROUND: In the EPIC-HR trial, nirmatrelvir plus ritonavir led to an 88% reduction in hospitalization or death among unvaccinated outpatients with early COVID-19. Clinical impact of nirmatrelvir plus ritonavir among vaccinated populations is uncertain. OBJECTIVE: To assess whether nirmatrelvir pl...

Descripción completa

Detalles Bibliográficos
Autores principales: Dryden-Peterson, Scott, Kim, Andy, Kim, Arthur Y., Caniglia, Ellen C., Lennes, Inga, Patel, Rajesh, Gainer, Lindsay, Dutton, Lisa, Donahue, Elizabeth, Gandhi, Rajesh T., Baden, Lindsey R., Woolley, Ann E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cold Spring Harbor Laboratory 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216724/
https://www.ncbi.nlm.nih.gov/pubmed/35734084
http://dx.doi.org/10.1101/2022.06.14.22276393

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9216724/
https://www.ncbi.nlm.nih.gov/pubmed/35734084
http://dx.doi.org/10.1101/2022.06.14.22276393

Ejemplares similares